Literature DB >> 29674492

11β-Hydroxysteroid Dehydrogenase 1 Human Tissue Distribution, Selective Inhibitor, and Role in Doxorubicin Metabolism.

Xin Yang1, Wenyi Hua1, Sangwoo Ryu1, Phillip Yates1, Cheng Chang1, Hui Zhang2, Li Di2.   

Abstract

11β-Hydroxysteroid dehydrogenase 1 (11β-HSD1) is distributed mainly in the human liver, with no detectable levels in the intestine or kidney, based on a newly developed proteomic approach. 11β-HSD1 is mostly membrane-bound and retained in the liver microsomal fraction. Interindividual variability of 11β-HSD1 is relatively low, with about a 3-fold difference. A significant correlation was not observed between various demographic variables (ethnicity, gender, age, weight, smoking, and alcohol use) and 11β-HSD1 protein expression or activity based on data from 31 donors. PF-915275 has been identified as a selective 11β-HSD1 inhibitor with minimal effects on carbonyl reductase 1 and major cytochrome P450 enzymes. 11β-HSD1 has been shown, for the first time, to be involved in doxorubicin metabolism, accounting for approximately 30% of doxorubicinol formation in human hepatocytes.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29674492     DOI: 10.1124/dmd.118.081083

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

1.  Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified.

Authors:  Daniel H Breysse; Ryan M Boone; Cameron M Long; Miranda E Merrill; Christopher M Schaupp; Collin C White; Terrance J Kavanagh; Edward E Schmidt; Gary F Merrill
Journal:  Drug Metab Dispos       Date:  2020-01-18       Impact factor: 3.922

Review 2.  11β-hydroxysteroid dehydrogenases: A growing multi-tasking family.

Authors:  Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2021-02-17       Impact factor: 4.102

3.  Metabolic Syndrome: Synergistic Risks for Doxorubicin-Induced Cardiotoxicity.

Authors:  Elise P Gomez-Sanchez
Journal:  J Cardiovasc Pharmacol       Date:  2021-12-01       Impact factor: 3.105

Review 4.  COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.

Authors:  B Robson
Journal:  Comput Biol Med       Date:  2020-04-11       Impact factor: 4.589

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.